2020
Reply to: Burosumab for Tumor‐Induced Osteomalacia: not Enough of a Good Thing
de Beur S, Miller PD, Weber TJ, Peacock M, Insogna K, Kumar R, Rauch F, Luca D, Cimms T, Roberts MS, San Martin J, Carpenter TO. Reply to: Burosumab for Tumor‐Induced Osteomalacia: not Enough of a Good Thing. Journal Of Bone And Mineral Research 2020, 36: 2455-2456. PMID: 34030212, PMCID: PMC9290665, DOI: 10.1002/jbmr.4317.Peer-Reviewed Original ResearchBurosumab for the Treatment of Tumor‐Induced Osteomalacia
de Beur S, Miller PD, Weber TJ, Peacock M, Insogna K, Kumar R, Rauch F, Luca D, Cimms T, Roberts MS, San Martin J, Carpenter TO. Burosumab for the Treatment of Tumor‐Induced Osteomalacia. Journal Of Bone And Mineral Research 2020, 36: 627-635. PMID: 33338281, PMCID: PMC8247961, DOI: 10.1002/jbmr.4233.Peer-Reviewed Original ResearchConceptsTumor-induced osteomalaciaCutaneous skeletal hypophosphatemia syndromeSerious adverse eventsAdverse eventsWeek 144Week 48Serum phosphorusTreatment-related adverse eventsFibroblast growth factor 23Surface/bone surfaceAcceptable safety profileOsteoid surface/bone surfacePhase 2 studyGrowth factor 23Phosphaturic mesenchymal tumorTransiliac bone biopsiesHuman monoclonal antibodyMineralization lag timePhosphate metabolismQuality of lifeDose titrationFactor 23Safety profileMesenchymal tumorsSkeletal healthNew Therapies for Hypophosphatemia-Related to FGF23 Excess
Athonvarangkul D, Insogna KL. New Therapies for Hypophosphatemia-Related to FGF23 Excess. Calcified Tissue International 2020, 108: 143-157. PMID: 32504139, DOI: 10.1007/s00223-020-00705-3.BooksConceptsTumor-induced osteomalaciaCutaneous skeletal hypophosphatemia syndromeEpidermal nevus syndromeAutosomal dominant hypophosphatemic ricketsAutosomal recessive hypophosphatemic ricketsHypophosphatemic ricketsForms of FGF23Treatment of XLHActive comparator trialsMainstay of therapyMonoclonal blocking antibodyNew treatment modalitiesMcCune-Albright syndromeRenal phosphate wastingRecessive hypophosphatemic ricketsDominant hypophosphatemic ricketsFGF23 excessComparator trialsSkeletal complicationsChronic hypophosphatemiaMusculoskeletal syndromeOngoing trialsClinical presentationTreatment modalitiesClinical trials
2019
Burosumab Improved Histomorphometric Measures of Osteomalacia in Adults with X‐Linked Hypophosphatemia: A Phase 3, Single‐Arm, International Trial
Insogna KL, Rauch F, Kamenický P, Ito N, Kubota T, Nakamura A, Zhang L, Mealiffe M, San Martin J, Portale AA. Burosumab Improved Histomorphometric Measures of Osteomalacia in Adults with X‐Linked Hypophosphatemia: A Phase 3, Single‐Arm, International Trial. Journal Of Bone And Mineral Research 2019, 34: 2183-2191. PMID: 31369697, PMCID: PMC6916280, DOI: 10.1002/jbmr.3843.Peer-Reviewed Original ResearchConceptsAdverse eventsWeek 48Fracture healingMore treatment-emergent adverse eventsTreatment-emergent adverse eventsProcedure-related adverse eventsOsteoid volume/bone volumeMost adverse eventsSerious adverse eventsTransiliac bone biopsiesSerum phosphorus concentrationPoor bone qualityRenal phosphate reabsorptionHuman monoclonal antibodyBone painPersistent osteomalaciaSubcutaneous burosumabPrimary endpointSkeletal complicationsAtraumatic fracturesChronic hypophosphatemiaSerum phosphorusDihydroxyvitamin DBone turnoverBone biopsy
2004
Fibroblast Growth Factor 7: An Inhibitor of Phosphate Transport Derived from Oncogenic Osteomalacia-Causing Tumors
Carpenter TO, Ellis BK, Insogna KL, Philbrick WM, Sterpka J, Shimkets R. Fibroblast Growth Factor 7: An Inhibitor of Phosphate Transport Derived from Oncogenic Osteomalacia-Causing Tumors. The Journal Of Clinical Endocrinology & Metabolism 2004, 90: 1012-1020. PMID: 15562028, DOI: 10.1210/jc.2004-0357.Peer-Reviewed Original ResearchMeSH KeywordsAdultBone NeoplasmsCD4 AntigensCell Line, TumorChildCulture Media, ConditionedFibroblast Growth Factor 7Fibroblast Growth Factor-23Fibroblast Growth FactorsGene Expression RegulationHumansInsulin-Like Growth Factor Binding Protein 4KineticsMaleMiddle AgedOsteomalaciaPhosphate Transport ProteinsConceptsFibroblast growth factor 7Tumor-derived culturesOncogenic osteomalaciaInhibitory activityRenal tubular epithelial cellsTubular epithelial cellsRenal phosphate transportPhosphate transportGrowth factor 7Tumor cell culturesRenal phosphate homeostasisNonconditioned mediumTumorsMonoclonal antibodiesEpithelial cellsDirect inhibitorFactor 7Phosphate homeostasisFGF familySyndromeCandidate mRNAsPotent inhibitorInhibitorsTransport inhibitionInhibitory
1984
Vitamin D metabolism and bone histomorphometry in a patient with antacid-induced osteomalacia
Godsall J, Baron R, Insogna K. Vitamin D metabolism and bone histomorphometry in a patient with antacid-induced osteomalacia. The American Journal Of Medicine 1984, 77: 747-750. PMID: 6486152, DOI: 10.1016/0002-9343(84)90378-4.Peer-Reviewed Original ResearchConceptsVitamin D metabolismD metabolismDihydroxyvitamin DBone histomorphometryNormal levelsAltered vitamin D metabolismPhosphate-binding antacidsVitamin D metabolitesHypophosphatemic osteomalaciaD metabolitesOsteomalaciaUndetectable levelsPatientsPossible roleHistomorphometryMetabolismMetabolitesHypophosphatemiaAntacidsPathogenesisIllnessResorptionElevated concentrationsLevelsIngestion
1980
Osteomalacia and Weakness From Excessive Antacid Ingestion
Insogna K, Bordley D, F. J, Lockwood D. Osteomalacia and Weakness From Excessive Antacid Ingestion. JAMA 1980, 244: 2544-2546. PMID: 7431592, DOI: 10.1001/jama.1980.03310220042025.Peer-Reviewed Original ResearchConceptsAluminum hydroxide-containing antacidElevated alkaline phosphatase levelsSerum calcium levelsAlkaline phosphatase levelsAntacid ingestionBone painPhosphate malabsorptionSevere hypophosphatemiaX-ray filmsInitial laboratory studiesPhysician awarenessUrinary phosphorusPatient's failureDietary phosphateCalcium levelsPhosphatase levelsOsteomalaciaFurther studiesHypercalciuriaHypophosphatemiaMalabsorptionPainAntacidsFailureSyndrome